Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Xing Bian,Xiaolin Wang,Qiuyan Zhang,Liying Ma,Guozhen Cao,Ao Xu,Jinhua Han,Jun Huang,Wenchu Lin

DOI: https://doi.org/10.3389/fonc.2023.1192526

IF: 4.7

2023-04-13

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.565820.].

oncology

What problem does this paper attempt to address?

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Yihui Zhou,Xiaomeng Gao,Yuan Meng,Bo Yang,Qiaojun He,Ji Cao

DOI: https://doi.org/10.3389/fphar.2021.785732

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2021.748852.].
Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Corrigendum: Multifunctions of CRIF1 in Cancers and Mitochondrial Dysfunction.

Yangzhou Jiang,Yang Xiang,Chuanchuan Lin,Weiwei Zhang,Zhenxing Yang,Lixin Xiang,Yanni Xiao,Li Chen,Qian Ran,Zhongjun Li

DOI: https://doi.org/10.3389/fonc.2023.1271492

IF: 4.7

2023-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1009948.].
Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Wan-Xin Peng,Fei Liu,Jia-Hong Jiang,Hang Yuan,Ziqiang Zhang,Liu Yang,Yin-Yuan Mo

DOI: https://doi.org/10.1016/j.gendis.2024.101352

2024-06-15

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2022.02.014.].
Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Pingping Ren,Luying Lu,Shasha Cai,Jianghua Chen,Weiqiang Lin,Fei Han

DOI: https://doi.org/10.3389/fimmu.2024.1513491

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.713540.].
Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Lin Wang,Xiang-Bo Ji,Li-Hong Wang,Jian-Ge Qiu,Feng-Mei Zhou,Wen-Jing Liu,Di-di Wan,Marie Chai-mi Lin,Ling-Zhi Liu,Jian-Ying Zhang,Bing-Hua Jiang

DOI: https://doi.org/10.3389/fcell.2022.1008088

IF: 5.5

2022-09-23

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2020.00840.].

cell biology,developmental biology
Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Xin Tian,Lina Wu,Min Jiang,Zhenyong Zhang,Rong Wu,Jianing Miao,Caigang Liu,Song Gao

DOI: https://doi.org/10.3389/fonc.2022.793448

IF: 4.7

2022-04-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.641399.].

oncology
Corrigendum: Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer

Huijuan Liu,Honglian Tao,Hongqi Wang,Yuyan Yang,Ru Yang,Xintong Dai,Xiujuan Ding,Haidong Wu,Shuang Chen,Tao Sun

DOI: https://doi.org/10.3389/fonc.2022.830506

IF: 4.7

2022-02-24

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.619317.].

oncology
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
The MYC Paralog-PARP1 Axis As a Potential TherapeuticTarget in MYC Paralog-Activated Small Cell Lung Cancer

Xing Bian,Xiaolin Wang,Qiuyan Zhang,Liying Ma,Guozhen Cao,Ao Xu,Jinhua Han,Jun Huang,Wenchu Lin

DOI: https://doi.org/10.3389/fonc.2020.565820

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Poly (ADP-ribose) polymerase 1 (PARP1) is highly expressed in small cell lung cancer (SCLC) and has emerged as an attractive target for treatment of SCLC. However, the clinical significance of PARP1 expression in SCLC remains elusive. In this study, we showed that high PARP1 expression was associated with better overall survival (OS), and was positively correlated with the expression of MYC paralogs in patients with SCLC. We demonstrated that PARP1 was transcriptionally regulated by MYC paralogs. Integrative analysis of multiple RNA-seq data sets indicated that DNA damage response (DDR) genes involved in the replication stress response (RSR) and homologous recombination (HR) repair pathways were highly enriched in MYC paralog-addicted SCLC cell models and in human SCLC specimens. Targeting the MYC paralog-PARP1 axis with concomitant BET and PARP inhibition resulted in synergistic effects in MYC paralog-activated SCLC. Our study identified a critical PARP1 regulatory pathway, and provided evidence for a rational combination treatment strategy for MYC paralog-activated SCLC.
Corrigendum: MYC Enhances Cholesterol Biosynthesis and Supports Cell Proliferation Through SQLE

Fan Yang,Junjie Kou,Zizhao Liu,Wei Li,Wenjing Du

DOI: https://doi.org/10.3389/fcell.2021.705769

IF: 5.5

2021-06-09

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2021.655889.].

cell biology,developmental biology
Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

Wei-Wei Zuo,Chun-Fang Zhao,Yan Li,Hai-Yan Sun,Guo-Ming Ma,Yue-Ping Liu,Shan Kang

DOI: https://doi.org/10.3389/fonc.2023.1218746

IF: 4.7

2023-06-27

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.931445.].

oncology
Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Wei Wang,Bo Hu,Jiang-Jiang Qin,Jianwen Cheng,Xin Li,Mehrdad Rajaei,Jia Fan,Xin-Rong Yang,Ruiwen Zhang

DOI: https://doi.org/10.1016/j.gendis.2019.12.006

IF: 7.376

2019-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2019.06.001.].
Corrigendum: EXOSC5 As a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer Via Activating the ERK and AKT Pathways

Hongda Pan,Jingxin Pan,Shibo Song,Lei Ji,Hong Lv,Zhangru Yang

DOI: https://doi.org/10.3389/fonc.2021.670041

IF: 4.7

2021-01-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2019.00643.].
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Yunfu Deng,Guangzhi Ma,Karin A. Vallega,Dongsheng Wang,Mingliang Wang,Changwei Wang,Shaomeng Wang,Suresh S. Ramalingam,Shi-Yong Sun

DOI: https://doi.org/10.1038/s41417-022-00479-w

IF: 5.854

2022-05-10

Cancer Gene Therapy

Abstract:Cancer Gene Therapy, Published online: 10 May 2022; doi:10.1038/s41417-022-00479-w Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Xuan Wei,Juanjuan Shi,Qianhan Lin,Xiaoxue Ma,Yingxin Pang,Hongluan Mao,Rui Li,Wei Lu,Yu Wang,Peishu Liu

DOI: https://doi.org/10.3389/fonc.2021.742374

IF: 4.7

2021-09-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.642229.].

oncology
Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

TingAn Wang,HuaGe Zhong,YuZhou Qin,WeiYuan Wei,Zhao Li,MingWei Huang,XiaoLing Luo

DOI: https://doi.org/10.1155/2021/3179693

2021-02-09

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2020/3575038.].

biotechnology & applied microbiology,medicine, research & experimental
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang,Bo-Ya Xiao,Peng-Cheng Li,Bo-Hua Kuang,Wang-Bing Chen,Pin-Dong Li,Guo-He Lin,Quentin Liu

DOI: https://doi.org/10.1155/2021/3735726

IF: 4.501

2021-02-25

Journal of Oncology

Abstract:[This corrects the article DOI: 10.1155/2020/2368164.].

oncology
Corrigendum: Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via miRNA-221/TP53INP1/p-ERK Axis

Xiaoqiang Liu,Zhengtao Zhou,Yibing Wang,Ke Zhu,Wen Deng,Yulei Li,Xiaochen Zhou,Luyao Chen,Yu Li,An Xie,Tao Zeng,Gongxian Wang,Bin Fu

DOI: https://doi.org/10.3389/fonc.2020.01735

IF: 4.7

2020-09-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00589.].

oncology
Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Xiu-Ying He,Yang Xu,Qing-Jie Xia,Xiao-Ming Zhao,Shan Li,Xiao-Qiong He,Ru-Rong Wang,Ting-Hua Wang

DOI: https://doi.org/10.3389/fonc.2022.872110

IF: 4.7

2022-03-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.663262.].

oncology

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Corrigendum: Targeting Myc Interacting Proteins As a Winding Path in Cancer Therapy

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Corrigendum: Multifunctions of CRIF1 in Cancers and Mitochondrial Dysfunction.

Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567]

Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Corrigendum: Downregulation of GLYAT Facilitates Tumor Growth and Metastasis and Poor Clinical Outcomes Through the PI3K/AKT/Snail Pathway in Human Breast Cancer

Corrigendum: Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

The MYC Paralog-PARP1 Axis As a Potential TherapeuticTarget in MYC Paralog-Activated Small Cell Lung Cancer

Corrigendum: MYC Enhances Cholesterol Biosynthesis and Supports Cell Proliferation Through SQLE

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum: EXOSC5 As a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer Via Activating the ERK and AKT Pathways

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Corrigendum: Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via miRNA-221/TP53INP1/p-ERK Axis

Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis